Taeyeop Lee1, Hochang Benjamin Lee2, Myung Hee Ahn1, Juyeon Kim3, Mi Sun Kim4, Sun Ju Chung5, Jin Pyo Hong6. 1. Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 2. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 3. Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 4. Clinical Nurse Specialist, Department of Neurology, Asan Medical Center, Republic of Korea. 5. Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: sunjubrain@gmail.com. 6. Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: suhurhong@gmail.com.
Abstract
INTRODUCTION: Parkinson's disease (PD) is a debilitating, neurodegenerative condition frequently complicated by psychiatric symptoms. Patients with PD may be at higher risk for suicide than the general population, but previous estimates are limited and conflicting. The aim of this study is to estimate the suicide rate based on the clinical case registry and to identify risk factors for suicide among patients diagnosed with PD. METHODS: The target sample consisted of 4362 patients diagnosed with PD who were evaluated at a general hospital in Seoul, South Korea, from 1996 to 2012. The standardized mortality ratio for suicide among PD patients was estimated. In order to identify the clinical correlates of suicide, case-control study was conducted based on retrospective chart review. The 29 suicide cases (age: 62.3 ± 13.7 years; females: 34.5%) were matched with 116 non-suicide controls (age: 63.5 ± 9.2 years; females 56.9%) by the year of initial PD evaluation. RESULTS: The SMR for suicide in PD patients was 1.99 (95% CI 1.33-2.85). Mean duration from time of initial diagnosis to suicide among cases was 6.1 ± 3.5 years. Case-control analysis revealed that male, initial extremity of motor symptom onset, history of depressive disorder, delusion, any psychiatric disorder, and higher L-dopa dosage were significantly associated with suicide among PD patients. Other PD-related variables such as UPDRS motor score were not significantly associated with death by suicide. CONCLUSION: Suicide risk in PD patients is approximately 2 times higher than that in the general population. Psychiatric disorders, and also L-dopa medication need further attention with respect to suicide.
INTRODUCTION:Parkinson's disease (PD) is a debilitating, neurodegenerative condition frequently complicated by psychiatric symptoms. Patients with PD may be at higher risk for suicide than the general population, but previous estimates are limited and conflicting. The aim of this study is to estimate the suicide rate based on the clinical case registry and to identify risk factors for suicide among patients diagnosed with PD. METHODS: The target sample consisted of 4362 patients diagnosed with PD who were evaluated at a general hospital in Seoul, South Korea, from 1996 to 2012. The standardized mortality ratio for suicide among PDpatients was estimated. In order to identify the clinical correlates of suicide, case-control study was conducted based on retrospective chart review. The 29 suicide cases (age: 62.3 ± 13.7 years; females: 34.5%) were matched with 116 non-suicide controls (age: 63.5 ± 9.2 years; females 56.9%) by the year of initial PD evaluation. RESULTS: The SMR for suicide in PDpatients was 1.99 (95% CI 1.33-2.85). Mean duration from time of initial diagnosis to suicide among cases was 6.1 ± 3.5 years. Case-control analysis revealed that male, initial extremity of motor symptom onset, history of depressive disorder, delusion, any psychiatric disorder, and higher L-dopa dosage were significantly associated with suicide among PDpatients. Other PD-related variables such as UPDRS motor score were not significantly associated with death by suicide. CONCLUSION: Suicide risk in PDpatients is approximately 2 times higher than that in the general population. Psychiatric disorders, and also L-dopa medication need further attention with respect to suicide.
Authors: Jared T Hinkle; Kate Perepezko; Zoltan Mari; Laura Marsh; Gregory M Pontone Journal: Am J Geriatr Psychiatry Date: 2018-01-31 Impact factor: 4.105
Authors: Melissa Deanna Shepard; Kate Perepezko; Martijn P G Broen; Jared Thomas Hinkle; Ankur Butala; Kelly A Mills; Julie Nanavati; Nicole Mercado Fischer; Paul Nestadt; Gregory Pontone Journal: J Neurol Neurosurg Psychiatry Date: 2019-01-19 Impact factor: 10.154
Authors: Wei Li; Masoom M Abbas; Sanchalika Acharyya; Hwee Lan Ng; Kay Yaw Tay; Wing Lok Au; Louis C S Tan Journal: Mov Disord Clin Pract Date: 2018-03-02
Authors: Ji Won Han; Yebin D Ahn; Won-Seok Kim; Cheol Min Shin; Seong Jin Jeong; Yoo Sung Song; Yun Jung Bae; Jong-Min Kim Journal: J Korean Med Sci Date: 2018-11-01 Impact factor: 2.153